159 related articles for article (PubMed ID: 32634267)
1. Cystoid macular edema following intravitreal chemotherapy treatment for retinoblastoma.
Panthagani J; Montecinos P; López JP; Parulekar M
Pediatr Blood Cancer; 2020 Sep; 67(9):e28348. PubMed ID: 32634267
[No Abstract] [Full Text] [Related]
2. Changes in Retinal Thickness on OCT from Intravitreal Melphalan.
Narala R; Kim JW; Lang P; Le BHA; Hendargo HC; Branco D; Berry JL
Ophthalmol Retina; 2019 Mar; 3(3):288-289. PubMed ID: 31014710
[No Abstract] [Full Text] [Related]
3. Diffuse chorioretinal atrophy after a single standard low- dose intravitreal melphalan injection in a child with retinoblastoma: a case report.
Chao A; Kao LY; Liu L; Wang NK
BMC Ophthalmol; 2016 Mar; 16():27. PubMed ID: 26975871
[TBL] [Abstract][Full Text] [Related]
4. Intravitreal melphalan hydrochloride vs propylene glycol-free melphalan for retinoblastoma vitreous seeds: Efficacy, toxicity and stability in rabbits models and patients.
Bogan CM; Pierce JM; Doss SD; Tao YK; Chen SC; Boyd KL; Liao A; Hsieh T; Abramson DH; Francis JH; Friedman DL; Richmond A; Daniels AB
Exp Eye Res; 2021 Mar; 204():108439. PubMed ID: 33444583
[TBL] [Abstract][Full Text] [Related]
5. Ocular toxicity of intravitreal melphalan for retinoblastoma in Chinese patients.
Xue K; Ren H; Meng F; Zhang R; Qian J
BMC Ophthalmol; 2019 Feb; 19(1):61. PubMed ID: 30808420
[TBL] [Abstract][Full Text] [Related]
6. Comparison of efficacy and toxicity of intravitreal melphalan formulations for retinoblastoma.
Hsieh T; Liao A; Francis JH; Lavery JA; Mauguen A; Brodie SE; Abramson DH
PLoS One; 2020; 15(7):e0235016. PubMed ID: 32609726
[TBL] [Abstract][Full Text] [Related]
7. ERG and OCT abnormalities in retinoblastoma after melphalan intravitreous injection.
Albuquerque ML; Moreto R; Bergamo M; Corrêa ZM; Jorge R
Arq Bras Oftalmol; 2022; 87(1):0037. PubMed ID: 35857974
[TBL] [Abstract][Full Text] [Related]
8. Intravitreal injection of melphalan for intraocular retinoblastoma.
Suzuki S; Aihara Y; Fujiwara M; Sano S; Kaneko A
Jpn J Ophthalmol; 2015 May; 59(3):164-72. PubMed ID: 25808017
[TBL] [Abstract][Full Text] [Related]
9. Local and systemic toxicity of intravitreal melphalan for vitreous seeding in retinoblastoma: a preclinical and clinical study.
Francis JH; Schaiquevich P; Buitrago E; Del Sole MJ; Zapata G; Croxatto JO; Marr BP; Brodie SE; Berra A; Chantada GL; Abramson DH
Ophthalmology; 2014 Sep; 121(9):1810-7. PubMed ID: 24819859
[TBL] [Abstract][Full Text] [Related]
10. Intravitreal HDAC Inhibitor Belinostat Effectively Eradicates Vitreous Seeds Without Retinal Toxicity In Vivo in a Rabbit Retinoblastoma Model.
Kaczmarek JV; Bogan CM; Pierce JM; Tao YK; Chen SC; Liu Q; Liu X; Boyd KL; Calcutt MW; Bridges TM; Lindsley CW; Friedman DL; Richmond A; Daniels AB
Invest Ophthalmol Vis Sci; 2021 Nov; 62(14):8. PubMed ID: 34757417
[TBL] [Abstract][Full Text] [Related]
11. Exudative Retinal Detachment Following Intravitreal Chemotherapeutic Treatment for Retinoblastoma.
Kotlyar B; Shapiro M; Blair M
Ophthalmic Surg Lasers Imaging Retina; 2019 Apr; 50(4):248-252. PubMed ID: 30998248
[TBL] [Abstract][Full Text] [Related]
12. Intravitreal melphalan for persistent or recurrent retinoblastoma vitreous seeds: preliminary results.
Shields CL; Manjandavida FP; Arepalli S; Kaliki S; Lally SE; Shields JA
JAMA Ophthalmol; 2014 Mar; 132(3):319-25. PubMed ID: 24407202
[TBL] [Abstract][Full Text] [Related]
13. Toxicity to intravitreal melphalan in a patient with retinoblastoma.
Solaz-Ruiz MG; Pérez LA; Cauto-Picazo C; Barranco-González H; Pascual-Camps I; España-Gregori E
Rom J Ophthalmol; 2023; 67(3):305-308. PubMed ID: 37876503
[No Abstract] [Full Text] [Related]
14. Retinoblastoma Control With Primary Intra-arterial Chemotherapy: Outcomes Before and During the Intravitreal Chemotherapy Era.
Shields CL; Alset AE; Say EA; Caywood E; Jabbour P; Shields JA
J Pediatr Ophthalmol Strabismus; 2016 Sep; 53(5):275-84. PubMed ID: 27486728
[TBL] [Abstract][Full Text] [Related]
15. Clinicopathologic review of enucleated eyes after intra-arterial chemotherapy with melphalan for advanced retinoblastoma.
Vajzovic LM; Murray TG; Aziz-Sultan MA; Schefler AC; Fernandes CE; Wolfe SC; Hess DJ; Dubovy SR
Arch Ophthalmol; 2010 Dec; 128(12):1619-23. PubMed ID: 21149791
[No Abstract] [Full Text] [Related]
16. Delayed Cerebral Infarction Following Intra-arterial Chemotherapy for Retinoblastoma.
De la Huerta I; Seider MI; Hetts SW; Damato BE
JAMA Ophthalmol; 2016 Jun; 134(6):712-4. PubMed ID: 27077487
[No Abstract] [Full Text] [Related]
17. TOXICITY AND EFFICACY OF INTRAVITREAL MELPHALAN FOR RETINOBLASTOMA: 25 µg Versus 30 µg.
Liao A; Hsieh T; Francis JH; Lavery JA; Mauguen A; Brodie SE; Abramson DH
Retina; 2021 Jan; 41(1):208-212. PubMed ID: 32106160
[TBL] [Abstract][Full Text] [Related]
18. Intravitreal melphalan for refractory or recurrent vitreous seeding from retinoblastoma.
Ghassemi F; Shields CL
Arch Ophthalmol; 2012 Oct; 130(10):1268-71. PubMed ID: 23044940
[TBL] [Abstract][Full Text] [Related]
19. Ocular side effects following intravitreal injection therapy for retinoblastoma: a systematic review.
Smith SJ; Smith BD; Mohney BG
Br J Ophthalmol; 2014 Mar; 98(3):292-7. PubMed ID: 24187047
[TBL] [Abstract][Full Text] [Related]
20. Intravitreal Melphalan for Treatment of Primary Vitreoretinal Lymphoma: A New Indication for an Old Drug.
Shields CL; Sioufi K; Mashayekhi A; Shields JA
JAMA Ophthalmol; 2017 Jul; 135(7):815-818. PubMed ID: 28617918
[No Abstract] [Full Text] [Related]
[Next] [New Search]
